证券代码：000710 证券简称：贝瑞基因 公告编号：2024-053 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人所持公司部分股份司法拍卖中止的公告 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 成都市贝瑞和康基因技术股份有限公司董事会 2024年10月30日 公司于 2024 年 10 月 10 日披露了《关于控股股东之一致行动人所持公司部分股 份将被司法拍卖的提示性公告》（公告编号：2024-048），成渝金融法院拟将公司控 股股东之一致行动人侯颖女士持有的公司 13,785,075 股股票于 2024 年 10 月 31 日 10：00 时起至 2024 年 11 月 1 日 10：00 时止在淘宝网司法拍卖网络平台上进行公开 拍卖（以下简称"本场司法拍卖"）。 1 2024 年 10 月 30 日，公司通过淘宝网司法拍卖网络平台查询获悉，因案外人异 议，本次司法拍卖中止。 公司将持续关注本场司法拍卖的进展情况，按照法律法规要求及时履行信息披 露义务，敬请投资者注意投资风险。 ...

Revenue and Profit - The company's revenue for Q3 2024 was ¥270,888,226.55, representing a decrease of 11.16% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥1,122,665.08, an increase of 102.82% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,322,198.94, up 110.12% from the previous year[2] - Total operating revenue for Q3 2024 was CNY 822,664,528.62, a decrease of 4.9% compared to CNY 865,605,843.90 in the same period last year[11] - Net profit for Q3 2024 was CNY 13,944,517.00, a significant recovery from a net loss of CNY 133,132,588.87 in Q3 2023[12] - Earnings per share for Q3 2024 was CNY 0.0294, compared to a loss per share of CNY -0.3806 in the same quarter last year[13] Cash Flow and Investments - The operating cash flow net amount for the year-to-date was ¥22,902,746.34, reflecting a significant increase of 254.55% compared to the same period last year[2] - The cash flow from investment activities for the year-to-date was ¥61,868,308.34, a substantial increase of 290.00% compared to the previous year[6] - The net cash flow from operating activities for Q3 2024 was ¥22,902,746.34, an increase from ¥6,459,630.18 in Q3 2023, reflecting improved operational efficiency[15] - Total cash inflow from investment activities was ¥309,503,280.00, significantly higher than ¥6,975,472.22 in the same period last year[15] - The net cash flow from investment activities was ¥61,868,308.34, recovering from a negative cash flow of -¥32,561,751.58 in Q3 2023[15] - The net cash flow from financing activities was -¥198,514,158.84, compared to -¥24,003,979.53 in Q3 2023, showing increased cash outflows for debt repayment[15] Assets and Liabilities - Total assets as of September 30, 2024, were ¥2,539,381,428.92, a decrease of 7.36% from the end of the previous year[2] - The company's equity attributable to shareholders increased to ¥1,874,087,697.69, a slight increase of 0.54% from the end of the previous year[2] - The company has a total of ¥1,595,574,893.32 in current assets, up from ¥1,472,996,759.37, an increase of approximately 8.3%[10] - The total liabilities decreased to CNY 631,315,936.19 from CNY 846,563,923.36 year-over-year[11] - The company's total liabilities decreased to ¥1,595,574,893.32 from ¥1,472,996,759.37, indicating a reduction in financial obligations[10] Shareholder Information - The total number of common shareholders at the end of the reporting period was 45,379[7] - The number of shares held by the top ten shareholders includes 12.45% by Chengdu Tianxing Instrument Group Co., Ltd. and 9.05% by Gao Yang[7] Operational Efficiency - The company reported a significant reduction in investment losses, with losses of CNY -6,798,926.38 compared to CNY -36,623,949.88 in the previous year[12] - Other comprehensive income for Q3 2024 was CNY -480,248.25, contrasting with CNY 3,176,915.40 in the same period last year[12] - The company aims to enhance market expansion and product development strategies in the upcoming quarters[11] Costs and Expenses - Total operating costs decreased to CNY 765,979,082.06, down 16.0% from CNY 911,575,255.95 year-over-year[11] - The company experienced a 60.39% reduction in financial expenses, amounting to ¥4,277,173.84, primarily due to loan repayments[5] - The cash paid for taxes rose to ¥53,753,798.64, up from ¥35,887,850.74 in Q3 2023, reflecting higher tax obligations[15] - The cash paid to employees increased slightly to ¥243,297,014.96 from ¥240,871,875.29 year-over-year[15] Inventory and Receivables - Accounts receivable increased to ¥1,064,985,647.45 from ¥807,950,441.91, representing a growth of about 31.7%[9] - Inventory decreased to ¥193,549,175.50 from ¥229,302,829.83, a reduction of approximately 15.6%[10] Audit Information - The company has not undergone an audit for the Q3 2024 report, as indicated in the financial statements[16]

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-050 成都市贝瑞和康基因技术股份有限公司 第十届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 表决结果：7 票同意，0 票反对，0 票弃权。 董事会认真审阅了《2024 年第三季度报告》，认为其内容真实、准确、完整， 不存在任何的虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网披露的《2024 年第三季度报告》。 三、备查文件 第十届董事会第十一次会议决议 特此公告。 成都市贝瑞和康基因技术股份有限公司董事会 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第十一次会议于 2024 年 10 月 28 日在北京市昌平区生命园路 4 号院 5 号楼 6 层 会议室以现场与通讯会议相结合的方式召开，会议通知已于 2024 年 10 月 25 日 以邮件形式发送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信 息。本次董事会会议应出席董事 7 名，实际出席会议董事 7 名，会议由董事长高 扬先生主持，董事会秘书 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-051 成都市贝瑞和康基因技术股份有限公司 第十届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开情况 特此公告。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届监事会 第七次会议于 2024 年 10 月 28 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场会议的方式召开，会议通知已于 2024 年 10 月 25 日以邮件形式发 送给各位监事，与会的各位监事均已知悉与所议事项相关的必要信息。本次监事 会会议应出席监事 3 名，实际出席会议监事 3 名，会议由监事会主席李翔东先生 主持，董事会秘书和证券事务代表列席了会议。会议的召开和表决程序符合有关 法律、行政法规、部门规章、规范性文件和公司章程的规定。 成都市贝瑞和康基因技术股份有限公司监事会 二、审议情况 1、审议《2024 年第三季度报告》 表决结果：3 票同意，0 票反对，0 票弃权。 监事会认真审阅了《2024 年第三季度报告》，认为其内容真实、准确、完整， 不存在任 ...

公司的染色体拷贝数变异数据分析软件（CNVisi®拷贝视界）是CNV-seq智 能化体系的重要组成部分，CNV-seq产品基于自主可控的高通量测序平台，具 有检测精准、范围全面、服务专业等优势，本数据分析软件能显著提升CNV解 产品名称 染色体拷贝数变异数据分析软件 注册人名称 杭州贝瑞和康基因诊断技术有限公司 注册证编号 浙械注准20242211896 注册分类 Ⅱ类 有效期 二〇二四年十月二十一日至二〇二九年十月二十日 适用范围 产品配套染色体拷贝数变异检测试剂盒（可逆末端终止测序法）使 用，将基因测序仪产生的脱氧核糖核酸（DNA）序列数据比对至人类 参考基因组并进行统计分析，获得染色体拷贝数变异情况的评价结 果。软件检测范围为孕妇的羊水样本中第13号、18号、21号、性染色 体的非整倍体，以及第15号染色体q11.2-q13区域、7号染色体q11.23区 域的缺失情况。 一、医疗器械注册证的基本情况 证券代码：000710 证券简称：贝瑞基因 公告编号：2024-049 成都市贝瑞和康基因技术股份有限公司 关于全资子公司染色体拷贝数变异数据分析软件取得医疗器械注册证的公告 本 公司及董事会全体成员保证信 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-048 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次拍卖标的物为公司控股股东之一致行动人侯颖女士持有的本公司 13,785,075 股股票，占其持有公司股份的比例为 92.39%，占公司总股本的比例为 3.90%。上述将被司法拍卖的股份均为无限售流通股，均已被司法冻结并已质押。 2、目前该拍卖事项尚在公示阶段，后续可能涉及竞拍、缴款、法院执行法定程 序、股权变更、过户等环节，存在一定的不确定性，公司将根据进展情况，依法履行 相应的信息披露义务。敬请广大投资者注意投资风险。 3、公司目前生产经营情况正常，该事项未对公司正常经营活动产生重大影响。 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"）于 近日收到控股股东之一致行动人侯颖女士发送的《成渝金融法院网络司法拍卖事项 通知书》并通过司法拍卖网络平台查询获悉，侯颖女士持有的公司部分股份将由成渝 金融法院于 2024 年 10 月 31 日 10：00 时起至 2024 年 11 月 1 日 10：00 时止 ...

| | 资金占用方 | 占用方与上市公 | 上市公司核算 | 2024 年期初 | 2024 年半年度占 | 2024 年半年度 | 2024 年半年度 | 2024 年半年度 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | | | | 用累计发生金额 | 占用资金的利息 | 偿还累计发生 | 期末占用资金 | | 占用性质 | | | 名称 | 司的关联关系 | 的会计科目 | 占用资金余额 | | | | | 原因 | | | | | | | | （不含利息） | （如有） | 金额 | 余额 | | | | 控股股东、实际控制人及 其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人 及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 其他关联方及其附属企业 | ...

一、担保情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"、"公 司"）于2023 年 10 月 27日召开第十届董事会第四次会议、2023年11月13日召开 2023年第四次临时股东大会审议通过了《关于公司及控股子公司担保额度预计的 议案》，同意公司为合并报表范围内子公司提供担保、子公司互相担保额度总计 不超过人民币 60,000 万元，并授权公司总经理在上述担保额度范围内，根据公 司及子公司实际日常经营资金需求办理担保事宜并签署相关文件，授权有效期 限与具体担保协议约定的保证期间一致，适用期限自股东大会审议通过之日起 至2024年12月31日止。 近日，公司全资子公司杭州贝瑞和康基因诊断技术有限公司（以下简称 "杭州贝瑞"）向杭州联合农村商业银行股份有限公司高沙支行申请综合授信 5,000万元，授信期限1年。为保证在上述授信额度内的全部债权能够得到清偿， 公司需为杭州贝瑞使用上述授信所形成的所有债务提供连带责任保证担保并签 署《最高额保证合同》（以下简称"本次担保"）。此外，公司控股股东高扬先 生为该笔授信提供个人连带责任保证担保。 成都市贝瑞和康基因技术股份有限公司 关于为控股子公司提供 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 551,776,302.07, a decrease of 1.59% compared to CNY 560,696,060.91 in the same period last year[10]. - Net profit attributable to shareholders was CNY 9,262,843.84, a significant increase of 109.74% from a loss of CNY 95,107,757.01 in the previous year[10]. - The net profit after deducting non-recurring gains and losses reached CNY 9,489,955.97, up 111.59% from a loss of CNY 81,863,981.19 in the same period last year[10]. - The net cash flow from operating activities was CNY 13,195,640.30, a remarkable increase of 317.05% compared to a negative cash flow of CNY 6,079,577.63 in the previous year[10]. - Basic and diluted earnings per share were both CNY 0.0262, recovering from a loss of CNY 0.269 per share in the same period last year, marking a 109.74% improvement[10]. - The total assets at the end of the reporting period were CNY 2,902,617,652.42, reflecting a growth of 5.89% from CNY 2,741,165,147.34 at the end of the previous year[10]. - The net assets attributable to shareholders increased to CNY 1,873,871,204.61, a slight rise of 0.53% from CNY 1,864,035,046.79 at the end of the previous year[10]. - The company achieved total revenue of ¥551,776,302.07, a decrease of 1.59% compared to the same period last year[28]. - Revenue from medical testing services was ¥199,449,499.48, a decrease of 10.88% year-on-year[28]. - Revenue from reagent sales increased by 21.29% to ¥257,599,110.45[28]. - Revenue from equipment sales decreased by 29.39% to ¥17,045,915.08[28]. - The company achieved a significant reduction in operating costs, which fell by 16.88% to ¥263,774,077.25[31]. - The gross margin for the genetic testing industry improved by 8.80% to 52.20% despite a slight decline in revenue[33]. - The company reported a net profit contribution of -¥448.96 million from the sale of assets, which accounted for 35.60% of total net profit[42]. Business Operations - The main business focus is on high-throughput sequencing technology-based genetic testing services, including sales of related equipment and reagents[15]. - The company offers a comprehensive range of genetic testing services, including non-invasive prenatal testing (NIPT) for chromosomal abnormalities and single-gene disorders, covering 153 diseases[15]. - The "贝比安 Plus" NIPT service screens for 17 types of fetal chromosomal abnormalities and 76 types of microdeletion syndromes, enhancing prenatal diagnostic capabilities[16]. - The company utilizes third-generation sequencing technology for various genetic tests, including screening for thalassemia and spinal muscular atrophy, improving diagnostic accuracy[16]. - The "贝新安" newborn genetic screening covers 103 genetic diseases, identifying pathogenic or potentially pathogenic variants in 358 target genes[16]. - The company is committed to the clinical application of genetic sequencing technology, focusing on reproductive health, genetic disease testing, and tumor detection[15]. - The company aims to expand its market presence by providing integrated "product + service" solutions to hospitals and research institutions[15]. - The company is actively developing new products and technologies to enhance its service offerings in the genetic testing market[15]. - The company has launched the world's first clinical-level liver cancer early screening product "Lai Si Ning," validated by a prospective cohort study involving over 10,000 participants[17]. - The multi-cancer early screening product "Quan Si Ning" can screen for six major high-risk cancers in China, utilizing cfDNA multi-dimensional whole genome sequencing technology[17]. - The company has established a comprehensive range of sequencing analysis services, leveraging platforms like Illumina NovaSeq X Plus and PacBio Revio, covering various research fields including tumor and genetic disease studies[18]. - The company’s NIPT library preparation reagents utilize the proprietary EZ-PALO rapid library preparation method, enhancing efficiency and simplicity[19]. - The NextSeq CN500 platform has been adopted by over 200 qualified medical institutions and third-party testing organizations for large-scale clinical genetic testing[21]. - The Sequel® II CNDx platform is currently in the medical device registration phase, aimed at detecting complex single-gene diseases, particularly thalassemia[21]. - The NovaSeqTM 6000Dx-CN-BG platform is also in the medical device registration phase, designed for whole genome sequencing (WGS) and whole exome sequencing (WES) applications[21]. - The company offers a variety of reagents, including NIPT DNA extraction and purification reagents, which are characterized by their rapid and efficient performance[20]. - The company focuses on high-throughput second and third-generation sequencing hardware platforms to drive reagent sales in genetic and tumor fields[21]. - The company has developed a range of sequencing reagents in collaboration with Illumina, ensuring stable and accurate performance[20]. Market and Competitive Landscape - The company faces risks from intensified market competition and declining service prices, which could impact its market share and future performance[48]. - The company is at risk of technological and product innovation lag, which may lead to decreased market share and profit margins if it fails to keep pace with industry advancements[49]. - The company reported a potential risk of declining gross margins due to increased competition and regulatory uncertainties in the gene sequencing industry[50]. - Accounts receivable are increasing rapidly due to the company's business expansion, posing a risk of bad debts and potential liquidity issues[50]. - The company is focusing on new project development to address gaps in its testing product line, which may cause performance fluctuations[49]. - The company is actively managing risks associated with overseas operations, including compliance with international regulations and potential geopolitical impacts[50]. Governance and Compliance - The company received administrative regulatory measures from the China Securities Regulatory Commission due to internal control and accounting issues[61]. - The company has implemented a comprehensive internal control rectification plan, including enhancing procurement management and sales management processes[63]. - A third-party professional institution has been hired to comprehensively review and improve the company's internal control system[63]. - The company has established a special group for accounts receivable recovery, focusing on background checks and risk assessments for clients[62]. - The company has improved its internal reporting procedures to ensure timely feedback of significant information across departments[63]. - The company has completed initial rectification measures and will continue to enforce compliance with internal control standards[64]. - The company reported that the rectification activities have positively impacted its governance structure and operational transparency[64]. - The company has emphasized the importance of compliance training for its management and staff to enhance operational awareness and internal control supervision[65]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the first half of 2024[54]. - A total of 85 employees participated in the employee stock ownership plan, holding a total of 2,823,000 shares, which represents 0.80% of the company's total equity[55]. - The first phase of the employee stock ownership plan has been extended for an additional 12 months, now set to expire on March 31, 2025[56]. - The total number of shares before the recent changes was 353,521,465, with a decrease of 18,233,989 shares due to the release of restricted shares, resulting in a new total of 318,258,593 shares[80]. - The proportion of restricted shares decreased from 15.13% to 9.97% after the changes, while the proportion of unrestricted shares increased from 84.87% to 90.03%[79]. - The company’s management has reduced their locked shares by 18,233,989, resulting in a new total of 35,262,872 restricted shares[80]. - The total amount of related party transactions for the reporting period was 30.88 million, with no significant impact on the company's financial status or independence[67]. Future Outlook and Strategy - The company plans to continue focusing on market expansion and new product development to drive future growth[100]. - The company is exploring potential mergers and acquisitions to strengthen its market position[116]. - The future outlook remains cautious due to market volatility and competitive pressures[116]. - The company has set performance guidance for the next quarter, anticipating a modest recovery in revenue growth[116]. Accounting and Financial Reporting - The financial statements are prepared based on the historical cost principle, ensuring reliable measurement of accounting elements[121]. - The company has not reported any significant events affecting its ability to continue operations[122]. - The company has undergone significant asset restructuring, acquiring 100% equity of Beijing Beirui and Kang Biotechnology Co., Ltd.[119]. - The stock name changed from "*ST Tianyi" to "Beirui Gene" following the completion of the asset restructuring[120]. - The company’s financial reporting is influenced by the judgments made regarding the timing and progress of performance obligations[199].

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-048 成都市贝瑞和康基因技术股份有限公司 第十届监事会第六次会议决议公告 监事会审阅了《2024 年半年度报告全文及摘要》，认为其内容真实、准确、 完整，不存在任何的虚假记载、误导性陈述或者重大遗漏。 2、审议通过《关于向参股公司提供借款的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届监事会 第六次会议于 2024 年 8 月 22 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场会议的方式召开，会议通知已于 2024 年 8 月 16 日以邮件形式发送 给各位监事，与会的各位监事均已知悉与所议事项相关的必要信息。本次监事会 会议应出席监事 3 名，实际出席会议监事 3 名，会议由监事会主席李翔东先生主 持，董事会秘书和证券事务代表列席了会议。会议的召开和表决程序符合有关法 律、行政法规、部门规章、规范性文件和公司章程的规定。 二、审议情况 1、审 ...